Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas
Details for Australian Patent Application No. 2009228616 (hide)
International Classifications
Event Publications
2 September 2010 PCT application entered the National Phase
PCT publication WO2009/118142 Priority application(s): WO2009/118142
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser